Table 4 Treatment, virus changes and outcomes of patients with COVID-19
|  | All patients (N = 91) | Local cases (n = 35) | Imported cases (n = 56) | P value |
|---|---|---|---|---|
Treatment | ||||
 Chinese traditional medicine | 91 (100.0%) | 35 (100.0%) | 56 (100.0%) | 1.000 |
 Antiviral therapy | 89 (97.8%) | 33 (94.3%) | 56 (100.0%) | 0.112 |
 Oxygen therapy | 46 (50.5%) | 14 (40.0%) | 32 (57.1%) | 0.306 |
 Intravenous immunoglobulin therapy | 22 (24.2%) | 5 (14.3%) | 17 (30.4%) | 0.081 |
 Thymosin alpha1 | 20 (22.0%) | 9 (25.7%) | 11 (19.6%) | 0.496 |
 Glucocorticoids | 13 (14.3%) | 3 (8.6%) | 10 (17.9%) | 0.218 |
 Intravenous antibiotic | 12 (13.2%) | 2 (5.7%) | 10 (17.9%) | 0.120 |
 Mechanical ventilation | 10 (11.0%) | 2 (5.7%) | 8 (14.3%) | 0.385 |
  Non-invasive (i.e., face mask) | 1 (1.1%) | 1 (2.9%) | 0 (0.0%) | 0.145 |
  Invasive | 9 (9.9%) | 1 (2.9%) | 8 (14.3%) | 0.385 |
ECMO | 1 (1.1%) | 1 (2.9%) | 0 (0.0%) | 0.145 |
Hospital stay, days, Median (IQR) | 14 (11–18) | 14 (11–17) | 15 (11–14) | 0.403 |
Duration of SARS-CoV-2 RNA positivity from onset | ||||
 Nasopharyngeal swabs, days | 11 (6–16) | 8 (5–16) | 12 (8–16) | 0.084 |
  Median (IQR), [range] | [1–39] | [1–37] | [4–39] |  |
 Feces, days | 79/91, 13 (10–19) | 29/35, 13 (6–18) | 50/56, 13 (10–20) | 0.216 |
  Median (IQR), [range] | [1–40] | [1–37] | [4–40] |  |
Duration of SARS-CoV-2 shedding from onset | ||||
 Nasopharyngeal swabs, days | 16 (13–23) | 15 (10–22) | 17 (14–23) | 0.148 |
  Median (IQR), [range] | [6–43] | [8–37] | [6–43] |  |
 Feces (days) | 79/91, 19 (14–26) | 29/35, 18 (11–24) | 50/56, 19 (15–27) | 0.242 |
  Median (IQR), [range] | [6–43] | [6–37] | [8–43] |  |
Clinical outcome | ||||
 Discharged | 88 (96.7%) | 34 (97.1%) | 54 (96.4%) | 1.000 |
 Died | 3 (3.3%) | 1 (1.1%) | 2 (3.6%) | 1.000 |